83861-29-4|GYKI-14451 sulfate|tert-butyl ((R)-1-((S)-2-(((S)-5-guanidino-1-oxopentan-2-yl)carbamoyl)pyrrolidin-1-yl)-1-oxo-3-phenylpropan-2-yl)carbamate hemisulfate|-范德生物科技公司

GYKI-14451 sulfate

NMR下载 COA and HPLC MSDS下载
names：
tert-butyl ((R)-1-((S)-2-(((S)-5-guanidino-1-oxopentan-2-yl)carbamoyl)pyrrolidin-1-yl)-1-oxo-3-phenylpropan-2-yl)carbamate hemisulfate
CAS号：
83861-29-4
MDL Number：
MF(分子式)： C50H78N12O14S MW(分子量)： 1103.304
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

货品编码	规格	纯度	价格 (¥)	现价(¥)	特价(¥)	库存描述	数量	总计 (¥)

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	GYKI-14451 sulfate
英文别名	GYKI-14451; GYKI 14451; GYKI14451; GYKI-14,451; GYKI 14,451; GYKI14,451; LY-178207; LY178207; LY 178207; Boc-D-Phe-Pro-Arg-H.
CAS号	83861-29-4
Inchi	InChI=1S/2C25H38N6O5.H2O4S/c21-25(2,3)36-24(35)30-19(15-17-9-5-4-6-10-17)22(34)31-14-8-12-20(31)21(33)29-18(16-32)11-7-13-28-23(26)27;1-5(2,3)4/h24-6,9-10,16,18-20H,7-8,11-15H2,1-3H3,(H,29,33)(H,30,35)(H4,26,27,28);(H2,1,2,3,4)/t2*18-,19+,20-;/m00./s1
InchiKey	QTXYFTMWQXMAQW-DCBJEQAZSA-N
分子式 Formula	C50H78N12O14S
分子量 Molecular Weight	1103.304
溶解度Solubility
性状	Solid powder
储藏条件 Storage conditions	Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years).

产品说明	GYKI-14451 sulfate(CAS:83861-29-4 ):仅限应用于工业或者科学研究过程中非医疗目的，不应用于人类或动物的临床诊断以及治过程疗，该产品非药用，非食用。
Introduction	GYKI-14451, also known as LY-178207, is a synthetic tripeptide inhibitor of thrombin with anti-atherosclerotic activity.
Application1
Application2
Application3

警示图
危险性	Warning
危险性警示
安全声明
安全防护
备注

[1]Callas DD, Fareed J. Direct inhibition of protein Ca by site directed thrombin inhibitors: implications in anticoagulant and thrombolytic therapy. Thromb Res. 1995 Jun 1;78(5):457-60. PubMed PMID: 7544924.

[2]Callas D, Iqbal O, Fareed J. Comparison of the anticoagulant activities of thrombin inhibitors as assessed by thromboelastographic analysis. Semin Thromb Hemost. 1995;21 Suppl

4:76-9. PubMed PMID: 8747693.

[4]Callas D, Bacher P, Iqbal O, Hoppensteadt D, Fareed J. Fibrinolytic compromise by simultaneous administration of site-directed inhibitors of thrombin. Thromb Res. 1994 May 1;74(3):193-205. PubMed PMID: 8042188.

[5] Barabas E, Szell E, Bajusz S. Screening for fibrinolysis inhibitory effect of synthetic thrombin inhibitors. Blood Coagul Fibrinolysis. 1993 Apr;4(2):243-8. PubMed PMID: 8499562.

5: Jackson CV, Wilson HC, Growe VG, Shuman RT, Gesellchen PD. Reversible tripeptide thrombin inhibitors as adjunctive agents to coronary thrombolysis: a comparison with heparin in a canine model of coronary artery thrombosis. J Cardiovasc Pharmacol. 1993 Apr;21(4):587-94. PubMed PMID: 7681904.

对不起，暂无产品评价！

MSDS

SDS 1.0 中文

展开

SDS 1.0 英文

展开